Table 2.
Microbiological and treatment features and outcome of Nocardia COVID-19 coinfected patients.
| Author (year) [reference] | Nocardia species | Sample | COVID treatment | Nocardia treatment | Outcome | |
|---|---|---|---|---|---|---|
| Colaneri (2021) [6] | Nocardia cyriacigeorgica | Blood culture | PIP/TAZ TMP/SMX | Linezolid, TMP/SMX and Ceftriaxone (one year) | Cure | |
| Laplace (2021) [7] | Nocardia cyriacigeorgica | Sputum | DXM 6 mg/24h, enoxaparin, cefotaxime | Imipenem and TMP/SMX | In hospital death | |
| Atemnkeng (2021) [8] | Nocardia asteroides | BAL | Azithromycin, ceftriaxone, REM, DXM y enoxaparin | Meropenem/linezolid TMP/SMX (one year) | Cure | |
| Arif (2021) [9] |
Nocardia farcinica |
Lung biopsy |
DXM 4mg oral |
TMP/SMX Meropenem/linezolid |
Discharged |
|
| Driscoll (2022) [10] | Nocardia farcinica | Bronchial secretion | Tobramycin, ceftazidime DXM | Linezolid | In hospital death | |
| Ortiz (2023) [Present case] | Nocardia spp | Sputum | REM (10 días), ceftriaxone DXM | Imipenem Ceftriaxone | Discharged | |
COVID-19: Coronavirus disease 2019. PIP/TAZ: Piperacillin/tazobactam. TMP/SMX: Trimethoprim/sulfamethoxazole. DXM: dexamethasone. BAL: bronchoalveolar lavage. CSF: Cerebrospinal fluid. REM: remdesivir.